Karvezide

Irbesartan, the active ingredient in Karvezide, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It treats hypertension in adult patients by relaxing blood vessels and reducing fluid retention. Hydrochlorothiazide, also present, is a thiazide diuretic that enhances the antihypertensive effect through increased urine output.

GNH USA supplies Karvezide as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Karvezide is employed to control high blood pressure by acting on the renin‑angiotensin system and promoting diuresis.

Essential hypertension: lowers systolic and diastolic pressure, reducing cardiovascular risk. Renovascular hypertension: improves blood pressure control by blocking angiotensin II‑mediated vasoconstriction. Hypertension with fluid retention: combines diuretic action to decrease extracellular volume and aid pressure reduction.

Karvezide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal upset

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Angioedema - Pancreatitis - Blood dyscrasias (e.g., agranulocytosis)

Before initiating Karvezide, several precautions should be considered to ensure safe use.

Blood pressure monitoring: check regularly to avoid excessive hypotension. Renal function assessment: evaluate kidney function before and during therapy. Electrolyte surveillance: monitor serum potassium and sodium levels. Pregnancy contraindication: not recommended in second and third trimesters (Category D). Drug interaction review: avoid concurrent use with potassium‑sparing diuretics without medical supervision. Store at room temperature: keep in the original container, protect from moisture and light.

Karvezide can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Potassium‑sparing diuretics: increased risk of hyperkalemia. - ACE inhibitors or ARBs combined with aliskiren in diabetic patients: heightened renal adverse events. - Lithium: elevated lithium levels and toxicity. - NSAIDs: may blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Other antihypertensives: additive blood‑pressure lowering may cause hypotension. - Corticosteroids: can enhance potassium loss. - Thyroid hormones: may modify diuretic response.